Suven Life Sciences Ltd Stock Price Today (NSE: SUVEN)
Suven Life Sciences Ltd
Fundamental Score
Suven Life Sciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Suven Life Sciences Ltd share price today is ₹131.70, down 2.75% on NSE/BSE as of 30 March 2026. Suven Life Sciences Ltd (SUVEN) is a Small-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of ₹3.93K (Cr). The 52-week high for SUVEN share price is ₹299.99 and the 52-week low is ₹113.99. The company has a Return on Equity (ROE) of -87.22% and a debt-to-equity ratio of 0.00.
Suven Life Sciences Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Suven Life Sciences Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Suven Life Sciences Share Price Analysis: A Deep Dive into ROCE Efficiency
The healthcare research, analytics, and technology sector is undergoing a significant shift, with a growing reliance on data-driven decision-making to optimize research and development (R&D) spending. Companies that can effectively leverage data to improve their Return on Capital Employed (ROCE) are poised for long-term success. This analysis explores the dynamics influencing the Suven Life Sciences share price, with a particular focus on the company's ROCE and its implications. Currently trading at ₹160.309998, Suven Life Sciences Ltd presents an interesting case study in profitability and capital allocation.
A critical metric for evaluating a company's efficiency is its Return on Capital Employed (ROCE). Suven Life Sciences currently reports a ROCE of -86.96%. This negative value suggests that the company is not generating profits from the capital it has employed. This significantly impacts the company's economic moat, indicating it lacks a strong competitive advantage in generating returns relative to its invested capital. A low or negative ROCE can also signal potential issues with operational efficiency or capital allocation strategies.
While a direct comparison of management quality requires a deeper qualitative assessment, we can contrast Suven Life Sciences Ltd with peers like
NOVELIX PHARMACEUTICALS LIMITE. If Novelix Pharmaceuticals exhibits a significantly higher ROCE, it could suggest more effective management strategies in capital deployment and operational execution. This difference, if sustained, might attract investors seeking superior returns on invested capital. Understanding the drivers behind these disparities is crucial for assessing the long-term sustainability of both companies.The impact of this negative ROCE on the Suven Life Sciences share price warrants further investigation. Investors often use ROCE as a key indicator of financial health and future profitability. A sustained negative ROCE can raise concerns about the company's ability to generate positive cash flow and sustain its operations. The absence of a PE ratio further underscores the lack of current profitability. This analysis is part of a broader 80-parameter fundamental audit, verified by Sweta Mishra, aimed at providing a comprehensive overview of the company's financial standing based on publicly available data. This is purely an observational analysis and should not be interpreted as investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Suven Life Sciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SUVEN across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (67.36%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
12 factors identified
Below-Average Return on Equity (-87.22%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-86.96%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-1086.16%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-55.74%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-64.20%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-12.00% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-14.08% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-24.19% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (-21188.00x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-672.93 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 4.56%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Suven Life Sciences Ltd Financial Statements
Comprehensive financial data for Suven Life Sciences Ltd including income statement, balance sheet and cash flow
About SUVEN (Suven Life Sciences Ltd)
Suven Life Sciences Ltd is a pioneering force in the healthcare sector, operating at the intersection of cutting-edge research, advanced analytics, and transformative technology. T...he company dedicates its efforts to unraveling the complexities of neurodegenerative diseases, particularly those affecting the central nervous system. Through rigorous scientific investigation and innovative drug discovery processes, Suven aims to identify and develop novel therapeutic interventions with the potential to significantly improve the lives of patients suffering from conditions like Alzheimer's disease and other neuropsychiatric disorders. Their commitment extends beyond the laboratory, as they actively engage in clinical trials and seek to translate scientific breakthroughs into tangible treatments accessible to patients worldwide. Suven’s approach leverages a blend of sophisticated analytical tools and a deep understanding of disease mechanisms. They meticulously analyze vast datasets to identify potential drug targets and optimize the development of new chemical entities. This data-driven approach, combined with a strong emphasis on intellectual property and strategic partnerships, allows Suven to navigate the challenging landscape of pharmaceutical development with agility and precision. Their research focuses on identifying innovative solutions that address unmet medical needs, striving to provide effective treatments that can slow down disease progression, alleviate symptoms, and ultimately enhance the quality of life for individuals and families affected by debilitating neurological conditions. Driven by a vision of a healthier future, Suven Life Sciences is committed to fostering a culture of scientific excellence and innovation. Their multifaceted operations encompass drug discovery, clinical development, and strategic commercialization planning, all while maintaining a focus on ethical research practices and patient-centered care. By embracing emerging technologies and continually refining their analytical capabilities, Suven positions itself as a dynamic player in the global healthcare arena, working tirelessly to advance the frontiers of neurological disease treatment and contribute to a more hopeful outlook for those affected by these challenging conditions.
Company Details
Key Leadership
Corporate Events
Latest News
SUVEN Share Price: Frequently Asked Questions
What is the current share price of Suven Life Sciences Ltd (SUVEN)?
As of 30 Mar 2026, 12:04 pm IST, Suven Life Sciences Ltd share price is ₹131.70. The SUVEN stock has a market capitalisation of ₹3.93K (Cr) on NSE/BSE.
Is SUVEN share price Overvalued or Undervalued?
SUVEN share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 45.95x. Based on this relative valuation, the Suven Life Sciences Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of SUVEN share price?
The 52-week high of SUVEN share price is ₹299.99 and the 52-week low is ₹113.99. These values are updated daily from NSE/BSE price data.
What factors affect the Suven Life Sciences Ltd share price?
Key factors influencing SUVEN share price include quarterly earnings growth (Sales Growth: -64.20%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Suven Life Sciences Ltd a good stock for long-term investment?
Suven Life Sciences Ltd shows a 5-year Profit Growth of -24.19% and an ROE of -87.22%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in SUVEN shares.
How does Suven Life Sciences Ltd compare with its industry peers?
Suven Life Sciences Ltd competes with major peers in the Healthcare Research, Analytics & Technology. Investors should compare SUVEN share price P/E of 0.00x and ROE of -87.22% against the industry averages to determine competitive standing.
What is the P/E ratio of SUVEN and what does it mean?
SUVEN share price has a P/E ratio of N/Ax compared to the industry average of 45.95x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is SUVEN performing according to Bull Run's analysis?
SUVEN has a Bull Run fundamental score of 6.5/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SUVEN belong to?
SUVEN operates in the Healthcare Research, Analytics & Technology industry. This classification helps understand the competitive landscape and sector-specific trends affecting Suven Life Sciences Ltd share price.
What is Return on Equity (ROE) and why is it important for SUVEN?
SUVEN has an ROE of -87.22%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Suven Life Sciences Ltd generates profits from shareholders capital.
How is SUVEN debt-to-equity ratio and what does it indicate?
SUVEN has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is SUVEN dividend yield and is it a good dividend stock?
SUVEN offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Suven Life Sciences Ltd shares.
How has SUVEN share price grown over the past 5 years?
SUVEN has achieved 5-year growth rates of: Sales Growth -12.00%, Profit Growth -24.19%, and EPS Growth -14.08%.
What is the promoter holding in SUVEN and why does it matter?
Promoters hold 67.36% of SUVEN shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Suven Life Sciences Ltd.
What is SUVEN market capitalisation category?
SUVEN has a market capitalisation of ₹3928 crores, placing it in the Small-cap category.
How volatile is SUVEN stock?
SUVEN has a beta of N/A. A beta > 1 suggests the Suven Life Sciences Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SUVEN operating profit margin trend?
SUVEN has a 5-year average Operating Profit Margin (OPM) of -1086.16%, indicating the company's operational efficiency.
How is SUVEN quarterly performance?
Recent quarterly performance shows Suven Life Sciences Ltd YoY Sales Growth of -64.20% and YoY Profit Growth of -55.74%.
What is the institutional holding pattern in SUVEN?
SUVEN has FII holding of 1.17% and DII holding of 3.39%. Significant institutional holding often suggests professional confidence in the Suven Life Sciences Ltd stock.